...
首页> 外文期刊>Pediatric nephrology: journal of the International Pediatric Nephrology Association >Protocol biopsies in pediatric renal transplant recipients on cyclosporine versus tacrolimus-based immunosuppression.
【24h】

Protocol biopsies in pediatric renal transplant recipients on cyclosporine versus tacrolimus-based immunosuppression.

机译:小儿肾移植受者接受环孢素与他克莫司的免疫抑制方案的活检。

获取原文
获取原文并翻译 | 示例

摘要

Protocol biopsies can detect subclinical rejection and early signs of calcineurin inhibitor-induced nephrotoxicity.In a prospective study, protocol biopsies 3 and 12 months after transplant in transplanted children from two centers were studied. One center used cyclosporine (CsA)-based immunosuppression and the other center used tacrolimus. Patients were on CsA (n?=?26, group 1) or on tacrolimus (n?=?10, group 2). Patients received basiliximab induction, mycophenolate mofetil, and prednisone.In patients on CsA, 26 kidney biopsies were performed during the 6 months after transplantation. Eighteen protocol biopsies were performed at 3 months post transplant; 13 were normal and five showed rejection (two borderline and three Banff II rejections). Eight biopsies were motivated by an increase of serum creatinine; four were normal and four revealed signs of acute rejection (two borderline and two Banff II). Twelve protocol biopsies were performed after 12 months; all were normal. For patients on tacrolimus (n?=?10), ten protocol transplant biopsies were performed at 3 months post-transplant; none showed signs of rejection. No biopsy was performed for an increase of serum creatinine. There were no differences in patient age, number of human leukocyteantigen (HLA) incompatibilities, or other patient characteristics.Patients on tacrolimus had less acute rejection episodes detected on protocol biopsies 3 months after transplant. Protocol biopsies seem to play an important role in the detection of subclinical rejection in patients on CsA.
机译:协议活检可以检测钙调神经磷酸酶抑制剂引起的肾毒性的亚临床排斥反应和早期迹象。在一项前瞻性研究中,研究了两个中心的被移植儿童在移植后3个月和12个月的协议活检。一个中心使用基于环孢素(CsA)的免疫抑制,另一个中心使用他克莫司。患者使用CsA(n?=?26,第1组)或他克莫司(n?=?10,第2组)。患者接受巴利昔单抗诱导,霉酚酸酯和强的松治疗。接受CsA治疗的患者在移植后的6个月中进行了26次肾脏活检。移植后3个月进行了18例活检。 13例正常,5例被拒绝(2例交界,3例Banff II拒绝)。血清肌酐水平升高导致了八次活检。 4例正常,有4例显示出急性排斥反应的迹象(2例交界和2例Banff II)。 12个月后进行12次协议活检;一切都很正常。对于他克莫司的患者(n = 10),在移植后3个月进行了10例协议活检。没有人显示出拒绝的迹象。没有进行活检以增加血清肌酐。在患者年龄,人类白细胞抗原(HLA)不相容性数量或其他患者特征方面无差异。他克莫司的患者移植后3个月在协议活检中检出的急性排斥反应较少。协议活检似乎在CsA患者亚临床排斥的检测中起重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号